Global Active Pharmaceutical Ingredients (API) Market · GlobeNewswire Inc. Dublin, Aug. 30, 2024 (GLOBE NEWSWIRE) -- The "Active Pharmaceutical Ingredients (API) - Global Strategic Business Report" ...

Teva Pharmaceuticals plans to remove 250 jobs at its CDMO unit over the next two years, Israeli business news outlet Globes ...

In the global pharmaceutical manufacturing landscape, HK Neopharm Limited has been increasingly recognized by industry observers as a noteworthy participant in the active pharmaceutical ingredient ...

QINGDAO, CHINA, January 19, 2026 /EINPresswire.com/ — As the pharmaceutical industry continues to evolve in the wake of pandemic-driven disruptions and heightened ...

KRTL Holding Group Inc. (OTC: KRTL) today announced the creation and strategic alignment of two coca-derived extract assets, ...

AI tools improve visibility, but pharma supply chains stay fragile when leaders favor cost and efficiency over ...

The Active Pharmaceutical Ingredients (API) Market plays a crucial role in the pharmaceutical industry, forming the backbone of drug development and production. APIs are the biologically active ...

India’s Torrent Pharma, which has been beefing up its international focused production capabilities, is buying an API operation from another Indian player. The Ahmedabad-based drugmaker today reported ...

The Active Pharmaceutical Ingredient (API) Market report delivers crucial insights into the market's growth trajectory and the primary revenue drivers anticipated between 2025 and 2034. As industries ...

BOCA RATON, Fla.--(BUSINESS WIRE)--LGM Pharma, a leading provider of tailored API and CDMO services for the full drug product life cycle, today reported that its unique mix of active pharmaceutical ...

Shanghai Pharmaceuticals has offered to acquire a majority stake, later to be followed by 100% ownership, in Changzhou Kony Pharma, a manufacturer of active pharmaceutical ingredients (APIs). Shanghai ...

MHRA approves Loba Biotech to manufacture Pegasys API, enabling pharma& to strengthen UK supply and ensure continued access for eligible patients. Following the MHRA decision, pharma& expects that ...